New England Journal of Medicine· 2021Q1· Clinical trial
Once-Weekly Semaglutide in Adults with Overweight or Obesity
- 4,614citations
- Q1SCImago
- 2021year
Short summary
A 68-week trial found that once-weekly semaglutide at 2.4 mg, combined with lifestyle changes, led to a significant average weight loss of 14.9% in adults with overweight or obesity, compared to 2.4% with placebo.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine